Responses
Clinical and epidemiological research
Extended report
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
Compose a Response to This Article
Other responses
No responses have been published for this article.